ProNAi Therapeutics (SRRA) Getting Somewhat Positive News Coverage, Study Finds

Press coverage about ProNAi Therapeutics (NASDAQ:SRRA) has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. ProNAi Therapeutics earned a news impact score of 0.23 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.9342118054989 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several research firms recently weighed in on SRRA. ValuEngine raised shares of ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research cut shares of ProNAi Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. Finally, Jefferies Group raised shares of ProNAi Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, October 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $4.00.

ProNAi Therapeutics (SRRA) opened at $3.00 on Tuesday. ProNAi Therapeutics has a 52 week low of $1.10 and a 52 week high of $3.41.

ProNAi Therapeutics (NASDAQ:SRRA) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.03. equities analysts expect that ProNAi Therapeutics will post -0.85 earnings per share for the current year.

WARNING: This story was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/12/05/pronai-therapeutics-srra-getting-somewhat-positive-news-coverage-study-finds.html.

ProNAi Therapeutics Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Insider Buying and Selling by Quarter for ProNAi Therapeutics (NASDAQ:SRRA)

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply